Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma

Han Chong Toh, Pei Jer Chen, Brian I. Carr, Jennifer J. Knox, Sharlene Gill, Peter Ansell, Evelyn M. McKeegan, Barry Dowell, Michelle Pedersen, Qin Qin, Jiang Qian, Frank A. Scappaticci, Justin L. Ricker, Dawn M. Carlson, Wei Peng Yong

Research output: Contribution to journalArticle

Abstract

Background: The efficacy and safety of linifanib (ABT-869), a selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinases, were assessed in this phase 2, single-arm, open-label, multicenter trial. Methods: Eligible patients had unresectable or metastatic hepatocellular carcinoma and had received ≤ 1 prior systemic therapy. Patients received oral linifanib at a fasting dose of 0.25 mg/kg,. The primary endpoint was the progression-free rate at 16 weeks. Tumor response was assessed every 8 weeks. Secondary endpoints included the time to disease progression, overall survival, and objective response rate. Safety was also assessed. Results: Of the 44 patients enrolled, the majority were Asian (89%), had received no prior systemic therapy (82%), had Child-Pugh class A hepatic function (86%), and had hepatitis B virus infection (61%). The estimated progression-free rate at 16 weeks was 31.8% (34.2% for patients with Child-Pugh class A hepatic function), the estimated objective response rate was 9.1% (10.5% for patients with Child-Pugh class A hepatic function), the median time to disease progression was 3.7 months (3.7 months for patients with Child-Pugh class A hepatic function), and the median overall survival was 9.7 months (10.4 months for patients with Child-Pugh class A hepatic function). The most common linifanib-related adverse events were diarrhea (55%) and fatigue (52%). The most common linifanib-related grade 3/4 adverse events were hypertension (25%) and fatigue (14%). Serum levels of biomarkers cancer antigen (CA) 125, cytokeratin fragment (CYFRA)21.1, and protein induced by vitamin K absence or antagonist II (PIVKA) demonstrated potential as prognostic indicators of patient response or outcome. Conclusions: Single-agent linifanib was found to be clinically active in patients with advanced hepatocellular carcinoma, with an acceptable safety profile.

Original languageEnglish
Pages (from-to)380-387
Number of pages8
JournalCancer
Volume119
Issue number2
DOIs
Publication statusPublished - Jan 15 2013

Keywords

  • angiogenesis
  • hepatocellular carcinoma (HCC)
  • linifanib
  • platelet-derived growth factor receptor (PDGFR)
  • sorafenib
  • vascular endothelial growth factor receptor (VEGFR)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Toh, H. C., Chen, P. J., Carr, B. I., Knox, J. J., Gill, S., Ansell, P., McKeegan, E. M., Dowell, B., Pedersen, M., Qin, Q., Qian, J., Scappaticci, F. A., Ricker, J. L., Carlson, D. M., & Yong, W. P. (2013). Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer, 119(2), 380-387. https://doi.org/10.1002/cncr.27758